Primary Prevention of Stroke in Children With Sickle Cell Anaemia in Nigeria in the Community (SPRING-COM)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05434000 |
Recruitment Status :
Recruiting
First Posted : June 27, 2022
Last Update Posted : June 27, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Sickle Cell Disease Stroke | Drug: Hydroxyurea | Not Applicable |

Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 217 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Other |
Official Title: | Primary Prevention of Stroke in Children With Sickle Cell Anaemia in Nigeria: Community vs Teaching Hospital |
Actual Study Start Date : | November 6, 2021 |
Estimated Primary Completion Date : | July 2024 |
Estimated Study Completion Date : | July 2025 |

Arm | Intervention/treatment |
---|---|
Children with sickle cell anaemia and abnormal TCD values (200cm/s)
The children identified with abnormal TCD values will be given hydroxyurea and followed for one year
|
Drug: Hydroxyurea
Children at risk of developing stroke (TCD values>200cm/s) will be given 20mg/kg of Hydroxyurea
Other Name: Oxyurea |
- Reach [ Time Frame: 1 year ]The portion of children than received TCD screening at least once in the community hospital
- Effectiveness [ Time Frame: 1 year ]The proportion of children with abnormal TCD measurement started on hydroxyurea
- Stroke occurrence [ Time Frame: 1 year ]Proportion of children with SCA identified with stroke.
- Clinical events among children on Hydroxyurea [ Time Frame: 1 year ]Proportion of children in both teaching and community hospitals with abnormal TCD (200cm/s) measurements receiving hydroxyurea with: i) pain crises ii) fever iii) acute chest syndrome and iv)severe anemia (Hgb <6g/dL).
- Clinical events among children not on Hydroxyurea [ Time Frame: 1 year ]Proportion of children with SCA not on hydroxyurea with: i) pain crises ii) fever iii) acute chest syndrome and iv) severe anemia (Hgb <6g/dL) in both teaching and community hospitals.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 2 Years to 16 Years (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Children with diagnosis of SCA (HbSS or HbSβthal0)
- 2-16 years receiving care at both YDMH (community hospital) and BDTH (teaching hospital).
- No previous stroke
Exclusion Criteria:
- Children with SCA younger than 2 years or older than 16
- Children with stroke
2) Children already on Hydroxyurea

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05434000
Contact: Halima Bello-Manga, MBBS,MPH | +2348033470592 | mamanzara@yahoo.co.uk | |
Contact: Bilya M Sani | +2348036005052 | bilyasani@yahoo.com |
Nigeria | |
Barau Dikko Teaching Hospital/Kaduna State University | Recruiting |
Kaduna, Nigeria | |
Contact: Halima Bello-Manga, MBBS, MPH +2348033470592 mamanzara@yahoo.co.uk | |
Contact: Bilya Sani, BSc +2348036005052 bilyasani@yahoo.com | |
Principal Investigator: Halima Bello-Manga, MBBS,MPH |
Principal Investigator: | Halima Bello-Manga, MBBS,MPH | Barau Dikko Teaching Hospital/Kaduna State University |
Responsible Party: | Barau Dikko Teaching Hospital |
ClinicalTrials.gov Identifier: | NCT05434000 |
Other Study ID Numbers: |
GRANT12968632 |
First Posted: | June 27, 2022 Key Record Dates |
Last Update Posted: | June 27, 2022 |
Last Verified: | June 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | The audiences most suitable for these results are persons affected with SCD and their families, health care providers, administrators, policy makers and other researchers in both SCD and implementation science. We believe dissemination of the results from this study will have immediate public health impact. The results will be published in high-impact journals like the New England Journal of Medicine, Lancet, Blood, American Journal of Hematology as well as presentations at National and International Scientific Conferences. The stakeholders in the community and teaching hospitals, and the State ministry of health will be provided with annual updates on study progress and interim results. We will also present study progress to the during the annual World Sickle Cell Day celebration, usually organized by community-based SCD support groups. |
Supporting Materials: |
Study Protocol Statistical Analysis Plan (SAP) Informed Consent Form (ICF) Clinical Study Report (CSR) |
Time Frame: | When study is completed |
Access Criteria: | Access will be granted with permission |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Sickle Cell Anaemia Stroke Transcranial Doppler Ultrasound Hydroxyurea Task-shifting |
Stroke Anemia Anemia, Sickle Cell Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases Vascular Diseases Cardiovascular Diseases Hematologic Diseases |
Anemia, Hemolytic, Congenital Anemia, Hemolytic Hemoglobinopathies Genetic Diseases, Inborn Hydroxyurea Antineoplastic Agents Antisickling Agents Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Nucleic Acid Synthesis Inhibitors |